Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- the year it was first approved in the U.S. -- some analysts predicted that it could generate as much as $25 billion in peak sales and become one of the best-selling drugs in the industry's history.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily to increase production.

Bengaluru: Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.The drug, which is an injectable medicine

Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site. The move is aimed at boosting the company’s production of biologic active ingredients, including those for its approved Alzheimer's treatment.

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs discussed earlier. Cancer drug Verzenio, type 2 diabetes drug Jardiance, and autoimmune disease drug Taltz are all blockbusters with strong sales momentum.

Eli Lilly and Company is expanding its manufacturing footprint in Ireland with a $1.8B investment to boost production of biologic active ingredients.

Key Takeaways Eli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and weight-loss drugs.The company's Alzheimer's drug, Kisunla, was approved by the U.S. Food and Drug Administration last month.

Eli Lilly and Company (NYSE:LLY) on Thursday announced a $1.8 billion investment to expand its manufacturing operations in Ireland. This decision will enhance the production of biologic active ingredients,